

October 28, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 6143-review.doc).

Title: Hepatitis C virus reactivation in cancer patients in the era of targeted therapies

Author: OzanYazici, Mehmet Ali Nahit Sendur, SercanAksoy

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 6143

We would like to thank to reviewers for their valuable criticisms. The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated and reference number typesetting were corrected

2 Revision has been made according to the suggestions of the reviewers

(1) Reviewer 1:

Comment 1: The discussion about mTOR inhibitors was detailed and some new sentences with references were added (highlighted with yellow). In literature, there is limiting data related to association between hepatitis C virus reactivation and tyrosine kinase inhibitors, brentixumab, anti-her-2 monoclonal antibodies, anti-EGFR therapies, and immunomodulating monoclonal antibodies. Therefore, we could not add extra information to some of these sections. The mTOR inhibitors section was detailed. The association with the use of everolimus and HCV reactivation was detailed. The possible relationship with temsirolimus and HCV reactivation was discussed.

Comment 2: The sections anti-EGFR therapies and anti-her-2 monoclonal antibodies were integrated.

Comment 3: The section related to TKI's was detailed. The data related to sorafenib, pazopanib and axitinib were added. Due to literature there was no direct relationship between the use of sorafenib, pazopanib, axitinib and HCV reactivation. However, imatinib was different. There was strong relationship between the use of imatinib and HBV reactivation. Also, one case of HCV reactivation under imatinib therapy was reported. The differences and similarities between TKIs were emphasized.

Comment 4: Abbreviations are corrected.

(2) Reviewer 2:

English language and spelling mistakes were corrected. The corrected words and sentences were highlighted with yellow.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,
SercanAksoy, MD,
Hacettepe University Cancer Institute,
Department of Medical Oncology,
Sihhiye Ankara 06100, Turkey.
Telephone: +90-312-305-2954
Fax: +90-312-324-2009
E-mail: saksoy07@yahoo.com



December 25, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 6143-review.doc).

Title: Hepatitis C virus reactivation in cancer patients in the era of targeted therapies

Author: OzanYazici, Mehmet Ali Nahit Sendur, SercanAksoy

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 6143

We would like to thank to reviewer 02105022 for valuable criticisms. The manuscript has been improved according to the suggestions of reviewer 02105022:

Reviewer 02105022:

We completely agree that treatment approaches for palliation and adjuvant intent should differentiate from each other.

The following sentences "However, it was important to distinguish the patients receiving treatment for cure or palliative intent. The monitoring of HCV RNA levels may differ in refractory lymphoma patients with limited survival expectancy. Usually, treatment is delivered with cure-intent in NHL patients. Therefore, close follow up strategy should be kept in mind for HCV infected NHL patients." "Especially, if HCV infected cancer patients had cure-intent targeted therapies, it is better to be more rigorous compared to patients with advanced cancer. Although there was no clear suggestion about follow up strategy of HCV reactivation in HCV infected advanced cancer patients, we recommend to extend the time interval between testing liver functions and HCV RNA levels." were added to conclusion part.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,



SercanAksoy, MD,
Hacettepe University Cancer Institute,
Department of Medical Oncology,
Sihhiye Ankara 06100, Turkey.
Telephone: +90-312-305-2954
Fax: +90-312-324-2009
E-mail: saksoy07@yahoo.com